Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 15:8:590768.
doi: 10.3389/fcvm.2021.590768. eCollection 2021.

Atrial Fibrillation and Cancer

Ludhmila Abrahao Hajjar  1 , Silvia Moulin Ribeiro Fonseca  1 , Theuran Inahja Vicente Machado  1
Affiliations
Review

Atrial Fibrillation and Cancer

Ludhmila Abrahao Hajjar et al. Front Cardiovasc Med. .

Abstract

Cancer patients have a higher risk of atrial fibrillation (AF) than general population, the pathophysiology mechanisms involves the pro inflammatory status of immune system in these patients and the exacerbated inflammatory response to cancer treatment and surgeries. Adequate management and prophylaxis for its occurrence are important and reduce morbidity and mortality in this population. There is a challenge in AF related to cancer to predict thromboembolic and bleeding risk in these patients, once standard stroke and hemorrhagic prediction scores are not validated for them. It is used CHA2DS2-VASc and HAS-BLED scores, the same as used in general population. In this review, we demonstrate correlated mechanisms to occurrence AF in cancer patients as well as therapeutic challenges in this population.

Keywords: anticoagulation; atrial fibrillation; cancer; cardiotoxicity; drug-drug interaction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Pathophysiology of AF in cancer patients.
See this image and copyright information in PMC

References

    1. Vedovati MC, Giustozzi M, Verdecchia P, Pierpaoli L, Conti S, Verso M, et al. . Patients with cancer and atrial fibrillation treated with DOACS: a prospective cohort study. Int J Cardiol. (2018) 269:152–7. 10.1016/j.ijcard.2018.07.138 - DOI - PubMed
    1. Cheng WL, Kao YH, Chen SA, Chen YJ. Pathophysiology of cancer therapy-provoked atrial fibrillation. Int J Cardiol. (2016) 219:186–94. 10.1016/j.ijcard.2016.06.009 - DOI - PubMed
    1. Chu G, Versteeg HH, Verschoor AJ, Trines SA, Hemels ME, Ay C, et al. . Atrial fibrillation and cancer – an unexplored field in cardiovascular oncology. Blood Rev. (2019) 35:59–67. 10.1016/j.blre.2019.03.005 - DOI - PubMed
    1. Lopez-Fernandez T, Martin-Garcia A, Rabadán IR, Mitroi C, Ramos PM, Diez-Villanueva P, et al. . Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol. (2019) 72:749–59. 10.1016/j.rec.2019.03.019 - DOI - PubMed
    1. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. (2014) 63:945–53. 10.1016/j.jacc.2013.11.026 - DOI - PubMed

LinkOut - more resources